Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vertex Pharmaceuticals Incorporated

< Previous 1 2 3 4 Next >
Vertex Reports Third Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Participate in Upcoming November Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Second Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Second Quarter 2024 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports First Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce First Quarter 2024 Financial Results on May 6
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Participate in Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.